The DOI matches its Crossref record; 285 of the 285 references it cites were found in a registry or an index.
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Open accessAbstract
Immune checkpoints are small molecules expressed by immune cells that play critical roles in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) with inhibitory antibodies has demonstrated effective and durable antitumor activity in subgroups of patients with cancer. The US Food and Drug Administration has approved several immune checkpoint inhibitors (ICPis) for the treatment of a broad spectrum of malignancies. Endocrinopathies have emerged as one of the most common immune-related adverse events (irAEs) of ICPi therapy. Hypophysitis, thyroid dysfunction, insulin-deficient diabetes mellitus, and primary adrenal insufficiency have been reported as irAEs due to ICPi therapy. Hypophysitis is particularly associated with anti-CTLA-4 therapy, whereas thyroid dysfunction is particularly associated with anti-PD-1 therapy. Diabetes mellitus and primary adrenal insufficiency are rare endocrine toxicities associated with ICPi therapy but can be life-threatening if not promptly recognized and treated. Notably, combination anti-CTLA-4 and anti-PD-1 therapy is associated with the highest incidence of ICPi-related endocrinopathies. The precise mechanisms underlying these endocrine irAEs remain to be elucidated. Most ICPi-related endocrinopathies occur within 12 weeks after the initiation of ICPi therapy, but several have been reported to develop several months to years after ICPi initiation. Some ICPi-related endocrinopathies may resolve spontaneously, but others, such as central adrenal insufficiency and primary hypothyroidism, appear to be persistent in most cases. The mainstay of management of ICPi-related endocrinopathies is hormone replacement and symptom control. Further studies are needed to determine (i) whether high-dose corticosteroids in the treatment of ICPi-related endocrinopathies preserves endocrine function (especially in hypophysitis), and (ii) whether the development of ICPi-related endocrinopathies correlates with tumor response to ICPi therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–285 of 285
Boasberg, P. D., Hoon, D. S. �., Piro, L. D., Martin, M. A., Fujimoto, A., Kristedja, T. S., Bhachu, S., Ye, X., Deck, R., & O'Day, S. J. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700545 · Cited by 99
Bednarczuk, T., Hiromatsu, Y., Fukutani, T., Jażdżewski, K., Miśkiewicz, P., Osikowska, M., & Nauman, J. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480013 · Cited by 98
Aleksova, J., Lau, P. K. H., Soldatos, G., & McArthur, G. A. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-217454 · Cited by 98
Amouzegar, A., Gharibzadeh, S., Kazemian, E., Mehran, L., Tohidi, M., & Azizi, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169283 · Cited by 98
Discovery of single-gene inborn errors of immunity by next generation sequencing
Conley, M. E., & Casanova, J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.05.004 · Cited by 94
Ling, V., Wu, P. W., Finnerty, H. F., Sharpe, A. H., Gray, G. S., & Collins, M. A. (1999) · Genomics · doi:10.1006/geno.1999.5930 · Cited by 94
Hansen, E., Sahasrabudhe, D. M., & Sievert, L. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1835-4 · Cited by 93
Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
Miyoshi, Y., Ogawa, O., & Oyama, Y. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.239.155 · Cited by 93
Rapid ACTH Test with Plasma Aldosterone Levels
Dluhy, R. G., HIMATHONGKAM, T., & GREENFIELD, M. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-6-693 · Cited by 91
The nonthyroidal illness syndrome in the non-critically ill patient
Παππά, Θ., Vagenakis, A. G., & Alevizaki, M. K. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02395.x · Cited by 90
Ferlito, A., Rinaldo, A., & Devaney, K. O. (1997) · Annals of Otology Rhinology & Laryngology · doi:10.1177/000348949710601014 · Cited by 89
McMillen, B., Dhillon, M. S., & Yong-Yow, S. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-214603 · Cited by 87
CTLA-4 polymorphisms in allergy and asthma and the TH1/ TH2 paradigm
Munthe‐Kaas, M. C., Carlsen, K. H., Helms, P. J. B., Gerritsen, J., Whyte, M. K. B., Feijen, M., Skinningsrud, B., Main, M., Kwong, G. N. M., Lie, B. A., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.03.050 · Cited by 83
Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT
Bacanovic, S., Burger, I. A., Stolzmann, P., Hafner, J., & Huellner, M. W. (2015) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000887 · Cited by 82
Torino, F., Barnabei, A., Vecchis, L. D., Salvatori, R., & Corsello, S. M. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0404 · Cited by 82
Munakata, W., Ohashi, K., Yamauchi, N., & Tobinai, K. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2101-4 · Cited by 81
Espenschied, J. R., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D. J., & Ellenhorn, J. D. I. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3401 · Cited by 79
Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33?q34
Lafage‐Pochitaloff, M., Costello, R. T., Couez, D., Simonetti, J., Mannoni, P., Mawas, C. E., & Olive, D. (1990) · Immunogenetics · doi:10.1007/bf00211556 · Cited by 79
Vaidya, B. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.688 · Cited by 79
Constitutive Association of SHP-1 with Leukocyte-Associated Ig-Like Receptor-1 in Human T Cells
Sathish, J. G., Johnson, K. G., FULLER, K. J., LeRoy, F. G., Meyaard, L., Sims, M., & Matthews, R. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1763 · Cited by 78
Kalogeras, K. T., Nieman, L. K., Friedman, T. C., Doppman, J. L., Cutler, G. B., Chrousos, G. P., Wilder, R. L., Gold, P. W., & Yanovski, J. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118640 · Cited by 78
Ni, R., Ihara, K., Miyako, K., Kuromaru, R., Inuo, M., Kohno, H., & Hara, T. (2007) · Human Genetics · doi:10.1007/s00439-006-0309-8 · Cited by 78
Mitchell, A. L., Cordell, H. J., Soemedi, R., Owen, K., Skinningsrud, B., Wolff, A. S. B., Ericksen, M., Undlien, D. E., Husebye, E. S., & Pearce, S. H. S. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1404 · Cited by 76
MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease
Allahabadia, A., Heward, J. M., Nithiyananthan, R., Gibson, S., Reuser, T., Dodson, P., Franklyn, J. A., & Gough, S. C. L. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06125-6 · Cited by 76
Nallapaneni, N. N., Mourya, R., Bhatt, V. R., Malhotra, S., Ganti, A. K., & Tendulkar, K. K. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0105 · Cited by 76
Ting, W., Chien, M.-N., Lo, F., Wang, C., Huang, C., Lin, C., Lin, W., Chang, T., Yang, H., Chen, W.-F., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154394 · Cited by 75
CD25+CD4+ regulatory T cells exert in vitro suppressive activity independent of CTLA-4
Kataoka, H., Takahashi, S., Takase, K., Yamasaki, S., Yokosuka, T., Koike, T., & Saito, T. (2005) · International Immunology · doi:10.1093/intimm/dxh221 · Cited by 73
Usui, Y., Udagawa, H., Matsumoto, S., Imai, K., Ohashi, K., Ishibashi, M., Kirita, K., Umemura, S., Yoh, K., Niho, S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.015 · Cited by 72
Furugaki, K., Shirasawa, S., Ishikawa, N., Ito, K., Ito, K., Kubota, S., Kuma, K., Tamai, H., Akamizu, T., Hiratani, H., et al. (2004) · Journal of Human Genetics · doi:10.1007/s10038-003-0120-5 · Cited by 71
Min, L., Vaidya, A., & Becker, C. (2011) · Endocrine Practice · doi:10.4158/ep11273.or · Cited by 66
Self-citationPhase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
Yamazaki, N., Kiyohara, Y., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Tsutsumida, A., Yoshikawa, S., Okuyama, R., Ito, Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2873-x · Cited by 66
Ban, Y., Tozaki, T., Taniyama, M., Tomita, M., & Ban, Y. (2005) · Autoimmunity · doi:10.1080/08916930500050319 · Cited by 65
Lack of Intrinsic CTLA-4 Expression Has Minimal Effect on Regulation of Antiviral T-Cell Immunity
Homann, D., Dummer, W., Wolfe, T., Rodrigo, E., Theofilopoulos, A. N., Oldstone, M. B. A., & von Herrath, M. G. (2005) · Journal of Virology · doi:10.1128/jvi.80.1.270-280.2006 · Cited by 62
Nivolumab induced myxedema crisis
Khan, U., Rizvi, H., Sano, D., Chiu, J., & Hadid, T. H. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0213-x · Cited by 61
Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma
Azmat, U., Liebner, D., Joehlin-Price, A., Agrawal, A., & Nabhan, F. (2016) · Case Reports in Endocrinology · doi:10.1155/2016/2087525 · Cited by 59
Tremelimumab-Induced Graves Hyperthyroidism
Gan, E. H., Mitchell, A. L., Plummer, R., Pearce, S., & Perros, P. (2017) · European Thyroid Journal · doi:10.1159/000464285 · Cited by 58
A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis
Yu, C. H., CHOPRA, I. J., & Ha, E. L. (2015) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-14-0092 · Cited by 57
Hayashi, M., Kouki, T., Takasu, N., Sunagawa, S., & Komiya, I. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0649 · Cited by 57
Guaraldi, F., Selva, R. L., Samà, M. T., D’Angelo, V., Gori, D., Fava, P., Fierro, M. T., Savoia, P., & Arvat, E. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0772-1 · Cited by 57
Tivol, E. A., & Gorski, J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.1852 · Cited by 55
Nielsen, C., Laustrup, H., Voss, A., Junker, P., Husby, S., & Lillevang, S. T. (2004) · Lupus · doi:10.1191/0961203303lu1052oa · Cited by 52
Verhagen, J., Gabryšová, L., Minaee, S., Sabatos, C. A., Anderson, G., Sharpe, A. H., & Wraith, D. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803186106 · Cited by 52
Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer
(2018) · In Vivo · doi:10.21873/invivo.11166 · Cited by 51
Pizarro, C., García‐Díaz, D. F., Ethel Codner, D., Salas‐Pérez, F., Carrasco, E., & Pérez‐Bravo, F. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2552 · Cited by 51
Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature
Hickmott, L., Peña, H. D. L., Turner, H. E., Ahmed, F., Protheroe, A. S., Grossman, A. B., & Gupta, A. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0480-y · Cited by 51
Fukuoka, H. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.011 · Cited by 50
Gunawan, F., George, E., & Roberts, A. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0146 · Cited by 49
Brunet, J., Denizot, F., & Golstein, P. (1988) · Immunological Reviews · doi:10.1111/j.1600-065x.1988.tb00747.x · Cited by 47
Case of type 1 diabetes associated with less‐dose nivolumab therapy in a melanoma patient
Teramoto, Y., Nakamura, Y., Asami, Y., Imamura, T., Takahira, S., Nemoto, M., Sakai, G., Shimada, A., Noda, M., & Yamamoto, A. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13486 · Cited by 47
Lee, F. Y., Covello, K. L., Castaneda, S., Hawken, D., Kan, D., Lewin, A. C., Wen, M.-L., Ryseck, R.-P., Fairchild, C. R., Fargnoli, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0025 · Cited by 44
Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
Li, L., Masood, A., Bari, S., Yavuz, S., & Grosbach, A. (2017) · Case Reports in Oncology · doi:10.1159/000456540 · Cited by 44
Brozzetti, A., Marzotti, S., Tortoioli, C., Bini, V., Giordano, R., Dotta, F., Betterle, C., Bellis, A. D., Arnaldi, G., Toscano, V., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0618 · Cited by 42
Deterioration of symptoms after start of thyroid hormone replacement
Murray, J., Jayarajasingh, R., & Perros, P. (2001) · BMJ · doi:10.1136/bmj.323.7308.332 · Cited by 41
Ishikawa, K., Saito‐Shono, T., Yamate, T., Yoshitaka, K. A. I., Sakai, T., Shimizu, F., Yamada, Y., Mori, H., Noso, S., Ikegami, H., et al. (2017) · European Journal of Dermatology · doi:10.1684/ejd.2016.2923 · Cited by 41
Alhusseini, M., & Samantray, J. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0042-119528 · Cited by 41
Araújo, M., Ligeiro, D., Costa, L., Marquês, F., Trindade, H., Correia, J. M., & Fonseca, C. (2017) · Immunotherapy · doi:10.2217/imt-2017-0020 · Cited by 40
The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFNγ
Paradis, T. J., Floyd, E., Burkwit, J., Cole, S. H., Brunson, B. L., Elliott, E. A., Gilman, S. C., & Gladue, R. P. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/s002620100181 · Cited by 39
The Long-Term Stability in Whole Blood of 14 Commonly-Requested Hormone Analytes
Diver, M. J., Hughes, J. G., Hutton, J. L., West, C. R., & Hipkin, L. J. (1994) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456329403100606 · Cited by 39
CTLA-4 and HLA gene susceptibility to thyroidassociated orbitopathy
Buzzetti, R., Nisticò, L., Signore, A., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(05)70596-1 · Cited by 37
Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma
Tsiogka, A., Jansky, G. L., Bauer, J. W., & Koelblinger, P. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000384 · Cited by 37
Case Report: Pembrolizumab-Induced Type 1 Diabetes in a Patient with Metastatic Cholangiocarcinoma
Smith-Cohn, M., Gill, D. M., Voorhies, B. N., Agarwal, N., & Garrido‐Laguna, I. (2017) · Immunotherapy · doi:10.2217/imt-2017-0042 · Cited by 37
HLA and CTLA4 polymorphisms may confer a synergistic risk in the susceptibility to Graves’ disease
Takahashi, M., & Kimura, A. (2010) · Journal of Human Genetics · doi:10.1038/jhg.2010.20 · Cited by 36
Marchand, L., Paulus, V., Fabien, N., Pérol, M., Thivolet, C. H., Vouillarmet, J., & Saintigny, P. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.021 · Cited by 36
Reisch, N., Reincke, M., & Bidlingmaier, M. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.080622 · Cited by 34
Matsumura, K., Nagasawa, K., Ôshima, Y., Kikuno, S., Hayashi, K., Nishimura, A., Okubo, M., Uruga, H., Kishi, K., Kobayashi, T., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12679 · Cited by 32
Kumagai, R., Muramatsu, A., Nakajima, R., Fujii, M., 戒能賢太, Katakura, Y., Okumura, N., Ohara, G., Kagohashi, K., Satoh, H., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12627 · Cited by 32
Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes
Kong, S. H., Lee, S. Y., Yang, Y., Kim, T. M., & Kwak, S. H. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0872-y · Cited by 30
Rapid Evolution of Thyroid Dysfunction in Patients Treated with Nivolumab
O’Malley, G., Lee, H. J., Parekh, S. S., Galsky, M. D., Smith, C. B., Friedlander, P. A., Yanagisawa, R. T., & Gallagher, E. J. (2017) · Endocrine Practice · doi:10.4158/ep171832.or · Cited by 29
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction
(2017) · In Vivo · doi:10.21873/invivo.11195 · Cited by 28
A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment
Humayun, M. A., & Poole, R. (2016) · HORMONES · doi:10.14310/horm.2002.1656 · Cited by 28
Thoreau, B., Gouaillier-Vulcain, F., Machet, L., et al. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2504 · Cited by 28
Wu, Z.-Q., & Xu, H. (2016) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22081 · Cited by 26
Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies
Way, J., Drakaki, A., Drexler, A., & Freeby, M. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-220415 · Cited by 26
Leonardi, G. C., Oxnard, G. R., Haas, A. V., Lang, J. P., Williams, J. S., & Awad, M. M. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000173 · Cited by 24
Alhusseini, M., & Samantray, J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.05.007 · Cited by 23
Torimoto, K., Okada, Y., Nakayamada, S., Kubo, S., & Tanaka, Y. (2017) · Thyroid · doi:10.1089/thy.2017.0062 · Cited by 20
Sharma, R. B., Dalmazi, G. D., & Caturegli, P. (2016) · Thyroid · doi:10.1089/thy.2016.0092 · Cited by 19
A Case of Hepatosplentic T Cell Lymphoma - A Rare, Aggressive Tumor of the Young.
Alzenaidi, A. A., Dendy, J., & Rejjal, L. (2017) · PubMed · Cited by 19
Addisonian crisis after thyroid replacement.
Banitt, P. F., & Munson, A. K. (1986) · PubMed · Cited by 18
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)
Corsello, S. M., Salvatori, R., Barnabei, A., Vecchis, L. D., Marchetti, P., & Torino, F. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2213-y · Cited by 17
Combination avelumab and utomilumab immunotherapy can induce diabetic ketoacidosis
Atkins, P., & Thompson, D. M. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.005 · Cited by 17
Bresler, S. C., Min, L., Rodig, S. J., Walls, A. C., Xu, S., Geng, S., Hodi, F. S., Murphy, G. F., & Lian, C. G. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.126 · Cited by 16
Self-citationFulminant type 1 diabetes mellitus associated with pembrolizumab
Mizab, C., Pérez, M. S., Rey, M. D. S., & García, M. H. (2017) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.01.005 · Cited by 14
Diabetes fulminante secundaria a tratamiento con pembrolizumab
Mizab, C., Pérez, M. S., Rey, M. D. S., & García, M. H. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.01.005 · Cited by 12
Adrenal insufficiency should be excluded before thyroxine replacement is started
Osman, I. A., & Leslie, P. (1996) · BMJ · doi:10.1136/bmj.313.7054.427 · Cited by 11
Cited by
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Chaker, L., Razvi, S., Bensenor, I. M., Azizi, F., Pearce, E. N., & Peeters, R. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00357-7 · Cited by 330
Choi, J., & Lee, S. Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e9 · Cited by 298
Hyperglycemic crises in adults with diabetes: a consensus report
Umpierrez, G. E., Davis, G. M., ElSayed, N. A., Fadini, G. P., Galindo, R. J., Hirsch, I. B., Klonoff, D. C., McCoy, R. G., Misra, S., Gabbay, R. A., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0032 · Cited by 278
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Metadata
- Authors
- Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2018-09-03
- Volume
- 40
- Issue
- 1
- Pages
- 17-65
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2891536507
- Cited by
- 532
- References
- 285
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.